Episode #46: JUPITER gets a battering, AVANDIA controversy spikes, EMA to review ARBs and cancer, clopidogrel response and cardiac death, ACC and AHA on clopidogrel label

This feature requires the newest version of Flash. You can download it here.

For our July 1, 2010 episode we focus on the following top news in cardiology from heartwire :

• JUPITER gets a battering, but Ridker fights back

• Another leaked rosiglitazone manuscript? Controversy spikes as JAMA, Archives publish new papers

• EMA to review ARBs and cancer, infuriating experts, who point to missing data and adverse consequences

• Low response to clopidogrel linked to increased risk of cardiac death after PCI

• No routine genetic or platelet-function testing for clopidogrel nonresponsiveness: ACC, AHA

And also, in brief:

• One in five stroke patients: No statins at discharge

• Genetic screening for familial hypercholesterolemia prevents coronary disease in Dutch study

• SATURN study to study efficacy of high-dose statins with IVUS

Join us for an audio recap of the news that's important to cardiologists this week.

Cite this: Episode #46: JUPITER gets a battering, AVANDIA controversy spikes, EMA to review ARBs and cancer, clopidogrel response and cardiac death, ACC and AHA on clopidogrel label - Medscape - Jul 01, 2010.